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Abstract
Background: To investigate whether Stiff-person syndrome (SPS) and cerebellar ataxia (CA) are associated with
distinct GAD65-Ab epitope specificities and neuronal effects.
Methods: Purified GAD65-Ab from neurological patients and monoclonal GAD65-Ab with distinct epitope
specificities (b78 and b96.11) were administered in vivo to rat cerebellum. Effects of intra-cerebellar administration
of GAD65-Ab were determined using neurophysiological and neurochemical methods.
Results: Intra-cerebellar administration of GAD65-Ab from a SPS patient (Ab SPS) impaired the NMDA-mediated
turnover of glutamate, but had no effect on NMDA-mediated turnover of glycerol. By contrast, GAD65-Ab from a
patient with cerebellar ataxia (Ab CA) markedly decreased the NMDA-mediated turnover of glycerol. Both GAD65-
Ab increased the excitability of the spinal cord, as assessed by the F wave/M wave ratios. The administration of
BFA, an inhibitor of the recycling of vesicles, followed by high-frequency stimulation of the cerebellum, severely
impaired the cerebello-cortical inhibition only when Ab CA was used. Moreover, administration of transcranial
direct current stimulation (tDCS) of the motor cortex revealed a strong disinhibition of the motor cortex with Ab
CA. Monoclonal antibodies b78 and b96.11 showed distinct effects, with greater effects of b78 in terms of increase
of glutamate concentrations, impairment of the adaptation of the motor cortex to repetitive peripheral stimulation,
disinhibition of the motor cortex following tDCS, and increase of the F/M ratios. Ab SPS shared antibody
characteristics with b78, both in epitope recognition and ability to inhibit enzyme activity, while Ab CA had no
effect on GAD65 enzyme activity.
Conclusions: These results suggest that, in vivo, neurological impairments caused by GAD65-Ab could vary
according to epitope specificities. These results could explain the different neurological syndromes observed in
patients with GAD65-Ab.
Background
Stiff person syndrome (SPS) is a rare neurological dis-
ease with features of an autoimmune disease. It is char-
acterized by progressive muscle stiffness, trigger-induced
spasms, spinal deformity, and high affinity autoantibo-
dies to the smaller isoform of glutamate decarboxylase
(GAD65-Ab) [1]. GAD65-Ab are also found in other
immune-mediated disorders affecting the central ner-
vous system (CNS), including some patients with cere-
bellar ataxia (CA) [2,3], and in the majority of patients
with autoimmune type 1 diabetes (T1D) [4]. While in
T1 D GAD65-Ab are mostly considered as indicators of
islet autoimmunity, in SPS a pathogenic role of GAD65-
Ab has been postulated based on the finding that they
inhibit the enzyme activity of GAD65 in vitro [5,6], and
their potential interference with GAD65-mediated trans-
port of GABA-containing vesicles to the presynapse
[7,8], both of which may lead to the reduced GABA
levels detected in cerebrospinal fluid and brain of SPS
patients [9].
A direct role of GAD65-Ab in the pathogenesis of neu-
rological disorders has been questioned because of the
assumed impermeability of neurons to immunoglobulins.
However, recent work demonstrated that antibodies can
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enabling the antibodies to bind intracellular antigens
[10,11].
We previously demonstrated that IgG purified from
GAD65-Ab positive patients with neurological syn-
dromes impair cerebellar activity and learning, and
affect spinal cord activity in rodents [12]. First, we
assessed the increase in the cortical motor response nor-
mally associated with repeated somatosensory stimula-
tion in rodents, an effect mediated by the cerebellum,
w h i c hi sc o n s i d e r e da saf i r s ts t e po fl e a r n i n gi nt h e
paradigm of sustained peripheral stimulation [13-15].
Administration of IgG isolated from GAD65-Ab positive
neurological patients induced repetitive muscle dis-
charges, abnormal exteroceptive reflexes and increased
F/M ratios, suggesting IgG-enhanced motoneuronal
excitability. Second, IgG isolated from GAD65-Ab posi-
tive neurological patients significantly impaired the
synaptic regulation of glutamate after N-methyl-D-
aspartate (NMDA) administration. IgG from GAD65-Ab
positive individuals without CNS involvement were inef-
fective in both models. Recently, Sommer et al. reported
that injections of rats with the IgG fraction of an SPS
patient with anti-amphiphysin antibodies resulted in a
dose-dependent stiffness with spasms mimicking those
of human SPS [16,17]. Taken together, these results
strongly support that SPS is directly caused by the effect
of antibodies on spinal cord neurons, both in anti-
amphiphysin and GAD65-Ab positive cases. However,
IgG from GAD65-Ab positive SPS patients and CA
patients caused the same types of dysfunction in the
cerebellum and in the spinal cord, leaving unexplained
why these patients typically develop distinct clinical pic-
tures, although some patients exhibit both syndromes
[18-20]. While immunotherapy and IgG-depleting stra-
tegies often alleviate symptoms of GAD65-Ab positive
SPS, symptoms of cerebellar dysfunction rarely improve
[20-22]. A possible explanation for this observation may
be distinct differences in the cascade of events induced
by antibodies and differences in the vulnerability of var-
ious sites in the CNS to GAD65-Ab. GAD65-Ab acting
upon cerebellar pathways might induce lesions reaching
an irreversible stage, with neuronal destruction and cer-
ebellar atrophy in a chronic situation. This hypothesis is
supported by the recent publication of an autopsy of a
patient with both CA and SPS showing only Purkinje
cells loss and no abnormalities in the spinal cord [19].
In the present study, we used IgG from GAD65-Ab
positive patients exhibiting CA or SPS and found differ-
ences between both diseases in the glycerol turnover, an
indicator of the turnover of cellular membranes. These
differences were enhanced by Brefeldin-A (BFA), an
inhibitor of the recycling of vesicles [23,24], when high-
frequency stimulation of the cerebellum, a depleting
procedure of vesicles, was applied. In addition, this pro-
cedure revealed differences in terms of cerebellocortical
inhibition and F/M ratios. This suggested that IgG from
GAD65-Ab-positive patients exert disease-specific levels
of impairment, possibly caused by different GAD65-Ab
epitope specificities. We tested this hypothesis using two
monoclonal GAD65-Ab with distinct epitope specifici-
ties, of which only one (b78) inhibits GAD65 enzyme
activity [25].
Methods
Antibodies
Polyclonal serum IgG isolated from GAD65-Ab positive
individuals
Sera were collected from a GAD65-Ab positive SPS
patient (Ab SPS) and a GAD65-Ab positive CA patient
(Ab CA). Control sera were obtained from a patient
with encephalitis (Ab Ctrl). None of the patients had T1
D. All sera were stored at -80°C. Experiments were per-
formed with IgG purified on protein A-Sepharose (pro-
tein A Sepharose 4 fast flow, Amersham Biosciences,
France). IgG were dialyzed overnight at 4°C against
Ringer’s solution (Frenesius Kabi, France) and sterilized
by filtration with 0.22 μm filters. Protein concentrations
were adjusted to 2.5 mg/ml. Five μl of the purified anti-
body (12.5 μg) were injected per experiment.
Monoclonal antibodies b78 and b96.11
Human monoclonal antibodies b96.11 and b78 specific to
GAD65 were derived from a patient with Autoimmune
Polyendocrine Syndrome Type 1 [26], and isolated from
supernatants of the respective B cell lines. The protein
concentration was adjusted to 1 mg/ml. Five μlo ft h e
purified antibody (5 μg) were injected per experiment.
The conformational epitope recognized by b96.11 is
bound by the majority of GAD65-Ab of T1 D patients
[27] and less frequently by GAD65-Ab present in
patients with SPS [25]. The conformational epitope
recognized by b78 is rarely bound by GAD65-Ab of T1
D patients, and is associated with GAD65-Ab in SPS
patients [25]. Notably, only b78 inhibits the enzyme
activity of GAD65 [25].
GAD65Ab epitope mapping
Recombinant [
35S]GAD65 was produced in an in vitro-
coupled transcription/translation system with SP6 RNA
polymerase and nuclease-treated rabbit reticulocyte
lysate (Promega, Madison, WI, USA) as described pre-
viously [28,29]. The in vitro-translated [
35S]GAD65 was
kept at -70°C and used within 2 wk. The capacity of the
recombinant Fab (rFab) of the above described GAD65-
specific monoclonal antibodies to compete with serum
GAD65-Ab for binding to [
35S]GAD65 was tested in a
competitive Radioligand binding assay (RBA) using pro-
tein A-Sepharose (Invitrogen, Carlsbad, CA, USA) as the
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was determined as less than 80% remaining binding
through the use of rFab D1.3 specific to Hen Egg
Lysozyme.
GAD65 enzyme activity assay
GAD65 activity was measured by the
14CO2-trapping
method described previously [30]. Recombinant human
GAD65 (100 ng) was incubated with reaction buffer (50
mM K2HPO4, 0.03 mM PLP, and 0.1 mM DTT (pH 6.8))
for 1 h at room temperature with or without serum (5-15
μl). The enzymatic reaction was initiated by the addition
of 0.56 mM L-glutamate and 0.018 μCi of
14C-glutamate
(Perkin Elmer, Waltham, MA, USA) and allowed to con-
tinue for 2 h at 37°C with gentle agitation. During incu-
bation, released
14CO2 was captured on filter paper
(Kontes Vineland, NJ, USA) soaked in 50 μlo f1M
NaOH. After the incubation, the absorbed radioactivity
was determined in a Beckman scintillation counter. The
results are presented as follows: percentage of residual
activity = counts per minute in the presence of serum/
counts per minute in the absence of serum × 100.
Animal studies
Animal studies were approved by the institutional ani-
mal care committee of the Free University of Brussels.
Experiments were conducted in male Wistar rats
(Charles River Laboratories; weight between 240 and
430 g). See Table 1 for a summary of the experiments
carried out.
Microdialysis procedure
This method has been explained earlier [12]. Briefly,
anesthetized animals were fixed in a stereotaxic appara-
tus (accuracy < 0.1 mm). The head was leveled and
secured by ear bars and a tooth holder. The skull was
exposed, scalp was shaved, cut sagitally and tissues over-
lying the cranium were removed. An intra-cerebellar
guide was implanted and fixed (coordinates of the extre-
m i t yo ft h eg u i d ew e r eA P :- 1 1 . 6 ,L :+ 2 . 3 ,V :- 4 . 6 ;a l l
coordinates are related to bregma according to the atlas
of Paxinos and Watson) (Figure 1). A CMA/10 probe
(length: 2 mm, diameter: 0.5 mm) was inserted in the
Table 1 Summary of experiments carried out
Experiments Purified IgG fractions/
Control solutions
Purified IgG
fractions/GAD65-
Ab
aModulation of motor
cortex excitability
No injection in 7 rats b78 in 4 rats
Ringer’s in 7 rats b96.11 in 4 rats
bCerebello-cortical
inhibition
Ab Ctrl in 4 rats Ab CA in 3 rats
Ab SPS in 3 rats
cF/M ratios Ab Ctrl in 4 rats Ab CA in 3 rats
No injection in 6 rats Ab SPS in 3 rats
Ringer’s in 6 rats b78 in 6 rats
b96.11 in 6 rats
aStudy of the modulation of the excitability of the motor cortex following
repetitive stimulation of the contralateral sciatic nerve;
bCerebello-cortical inhibition following high-frequency stimulation of the
cerebellar cortex and following transcranial direct current stimulation (tDCS).
cStudy of the ratios F waves/M response following stimulation of the left tibial
nerve and recording in the plantaris muscle.
Figure 1 Illustration of bilateral implantation of cerebellar
guides. A: Two holes (black arrows) in the skull to implant the
guides. B: Probes are inserted in cerebellar nuclei (CN). C: Bilateral
injection of Ab. Brain sections at the level of cerebellar nuclei in B
and C.
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pump and perfused with Ringer’sa taf l o wr a t eo f2μL/
min. A volume of 5 μL of solution was injected over a
period of 5 minutes through the guide. The probe was
then reinserted in the guide (CMA12, Carnegie Medicin
AB, Sweden) and continuously perfused with Ringer’sa t
a flow rate of 2 μL/min. All animals underwent cerebellar
surgery on the left side. At the end of the experiments,
an overdose of chloral hydrate was administered and the
brain was removed for histological verification of the
location of the probe [12]. Experiments with misplace-
ments of the probes were excluded. For experiments with
administration of BFA, a bilateral targeting of cerebellar
nuclei procedure was applied. For these experiments,
each rat received the Ab followed by BFA on one side,
and the Ab followed by Ringer’s contralaterally.
Glutamate, glucose, lactate, pyruvate and glycerol
measurements
After stabilization of baseline measurements, samples
were collected every 20 minutes to measure the extra-
cellular concentrations of glutamate, glucose, lactate,
pyruvate and glycerol. We used the CMA/600 device
(Aurora Borealis Control; glutamate oxidase method) for
the quantitative determination of metabolites in micro-
dialysates [31].
Mapping of corticospinal responses
Stimuli (square wave of 1 msec duration) were first
applied every mm in the sagittal axis and every 0.5 mm
in the coronal axis to obtain a matrix of 6 × 9 sites of
stimulation, [32] to identify the “hot spot” correspond-
ing to the largest motor evoked potential. We subse-
quently used the location of 3 mm laterally and 0.5 mm
posterior to bregma for stimulation of the motor cortex,
consistent with stimulation sites in other studies [14,33].
Recruitment curves (detection of motor threshold MT
defined as the lowest intensity eliciting at least 5 out of
10 evoked responses with an amplitude >20 μVolts, fol-
lowed by increases of the intensity of stimulation with
steps of 0.1 mAmp until maximum) of corticomotor
responses were analyzed to confirm the classical sigmoid
course [34]. Motor cortex was stimulated at an intensity
of 130% of MT to assess latencies and amplitudes of
corticomotor potentials.
Modulation of motor cortex excitability following peripheral
repetitive stimulation
We investigated the motor evoked responses (MEPs:
motor evoked potentials) in the left gastrocnemius mus-
cle following stimulation of the contralateral motor cor-
tex, before (basal condition) and after repetitive
electrical stimulation of the left sciatic nerve [13,14].
Chloral hydrate was administered continuously at 2 μL/
min (CMA100 micropump; CMA, Sweden) using the i.
p. route [2]. Anesthesia depth was adjusted for absence
of abdominal contractions in response to tail pinch. The
left sciatic nerve was surgically exposed for bipolar sti-
mulation. Duration of stimulation was one hour. Trains
of stimulation were delivered at a rate of 10 Hz (a train
b e i n gc o m p o s e do f5s t i m u l io fa1m s e cd u r a t i o n ;
A310-A365 stimulator - World Precision Instruments,
UK). Stimulus intensity was adjusted to produce con-
stant somatosensory evoked potentials (SEP) in the EEG
[14]. For the stimulation of the motor cortex, square sti-
muli were applied at the level of the motor cortex [15].
Peak-to-peak amplitudes in motor responses of the con-
tralateral gastrocnemius muscle were studied. Filter set-
tings were 30 Hz-1.5 KHz (NeuroMax 4, Xltek, Canada).
Transcranial direct current stimulation (tDCS)
The methodology is described elsewhere [32]. Cortico-
motor responses evoked in the gastrocnemius muscle
following stimulation of the contralateral motor cortex,
before (basal condition) and after application of trains of
tDCS were studied. The amplitudes of corticomotor
responses were also studied in the contralateral side
(gastrocnemius muscle) before and after tDCS over left/
right motor cortex (random selection of side of stimula-
tion was applied). Peak-to-peak amplitudes in motor
responses of the left (right) gastrocnemius muscle were
studied before and after tDCS for 10 corticomotor
responses. We used subcutaneous electrodes (Tech-
nomed 017K025) implanted in muscles. We obtained
similar results by folding wires (Wire silver, AGT0510,
World Precision Instruments) into flat plates implanted
into a subcutaneous pocketo v e rt h eg a s t r o c n e m i u s
muscle [14]. Trains of electrical stimuli were applied on
the skull with the anode placed at the level of the right
(left) motor cortex, just anteriorly to the site of stimula-
tion used to obtain corticomotor responses. For anodal
stimulation, we followed the protocol by Fregni et al. to
obtain a contact area of 7.1 mm
2 [35]. The cathode (dia-
meter 0.8 mm) was placed ipsilaterally on the supraorbi-
tal region (inter-electrode distance: 5 mm). Duration of
stimulation was 20 minutes [36] (a duration of stimula-
tion of 7 minutes at 1 mA is known to induce signifi-
cant changes of motor cortical excitability in human).
Stimulus intensity was 0.4 mAmp. tDCS was applied
directly onto the cranium to ensure a defined contact
area over the cortex.
Cerebello-cortical inhibition
Stimulation of the cerebellum inhibits motor cortex
activity [37]. To assess the cerebello-cortical inhibition,
the dura around the cerebellum was exposed and the
insertion of cervical muscles was cut to avoid the affer-
ent volley from these muscles. An electrical stimulus
was applied over the cerebellum (4 concomitant sites of
stimulation; A310-A365 stimulator) followed by a sec-
ond stimulus applied contralateral over the motor cortex
after 2.1 msec delay. This delay was first determined
according to the inhibition/inter-stimulus interval (ISI)
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cortical inhibition was performed after administration of
antibodies, following high frequency stimulation of the
cerebellum, and following applications of trains of tDCS.
Each duo of conditioned/unconditioned response was
assessed 10 times to compute the average.
F-waves and M response
The F-waves and the direct motor responses (M response)
were studied as described [38]. Electrical stimulation of
the left tibial nerve was achieved through a pair of needle
electrodes inserted subcutaneously at the ankle, behind
the medial malleolus. Electrical stimuli consisted of single
square-wave shocks of 0.5 msec duration, delivered every
6 seconds. EMG recordings were obtained from the ispi-
lateral plantaris muscle through a pair of needle electrodes
inserted in the distal third of the sole (filters 30 Hz-1.5
KHz). We assessed the ratio mean F/mean M wave ampli-
tudes following 50 supramaximal stimuli [13,39]. We ana-
lyzed these ratios after administration of antibodies,
following high-frequency stimulation of the cerebellar cor-
tex, and following application of trains of tDCS.
Statistical analysis
The levels of glutamate, glucose, lactate/pyruvate ratios,
and glycerol levels during infusion of NMDA were com-
pared with the analysis of variance. The effects of Ab on
the cerebello-cortical inhibition were compared using the
analysis of variance, followed by multiple comparison
procedure (Holm-Sidak test). The effects of repetitive
peripheral stimulation on the amplitude of motor evoked
potentials were evaluated in each group of rats (controls,
administration of Ringer’s, b78, or b96.11) using the Stu-
dent t-test. We also used the analysis of variance to com-
pare the groups. The mean F/mean M response ratio was
compared using the analysis of variance, followed by
multiple comparison procedure (as above).
Results
Patients’ antibodies CA/SPS/Ctrl
Metabolites in cerebellar nuclei
Ab SPS increased dramatically the extracellular gluta-
mate level during intra-nuclear infusion of NMDA, as
compared to Ab CA and Ab Ctrl (p < 0.001) (Figure 2).
By contrast, there was no difference in glucose turnover
or lactate/pyruvate ratios, indicating that the antibodies
did not impair the energy metabolism in cerebellar
nuclei. Interestingly, the glycerol turnover was markedly
r e d u c e dw i t hA bC Aa sc o m p a r e dt oA bC t r l( p<
0.001) and Ab SPS (p < 0.001). These results suggested
that Ab CA and Ab SPS exerted different effects upon
GAD65 activity and cellular membranes turnover.
Sigmoidal fitting
An example of the sigmoidal fitting of recruitment
curves of MEPs is illustrated in Figure 2. In each case
(Ab Ctrl, Ab CA, and Ab SPS), a significant sigmoidal
fit was obtained.
Cerebello-cortical inhibition
With Ab CA, cerebello-cortical inhibition remained
unchanged following infusion of Ringer’s, but decreased
following administration of BFA and high-frequency sti-
mulation of the cerebellar cortex (Figure 3A-F). This
phenomenon was not observed with Ab Ctrl, or Ab SPS.
Ratios of amplitudes of conditioned responses divided
by amplitudes of unconditioned responses for the differ-
ent groups of rats are illustrated (Figure 4).
Effects of tDCS
Ab CA induced marked impairment of corticomotor
excitability following the administration of high-fre-
quency cerebellar stimulation (Figure 5). Indeed, trains
of tDCS unraveled a spreading of high-level excitability
areas of the motor cortex contralaterally to the adminis-
tration of Ab CA. This phenomenon was not observed
with Ab SPS or with Ab Ctrl.
Skeletal muscle/spinal cord function
BFA did not impair the Mean F/Mean M ratios in rats
receiving Ab Ctrl, including when the high-frequency
stimulation of the cerebellum or trains of tDCS were
applied (Figure 6). In contrast, the administration of Ab
CA and Ab SPS increased the Mean F/M ratios. Mean
F/M ratios increased markedly following high-frequency
stimulation of the cerebellar cortex after administration
of Ab CA and BFA. The increase was even stronger fol-
lowing tDCS of the motor cortex.
GAD65 enzyme inhibition serum and GAD65Ab epitope
pattern
Inhibition of GAD65 enzyme activity by Ab CA, Ab
SPS, and Ab Ctrl was tested (Figure 7A). GAD65
enzyme activity was significantly inhibited by Ab SPS
only (50%), while Ab CA had no effect on the enzyme
activity. GAD65 binding by Ab SPS was significantly
reduced in the presence of rFab b96.11 (59% of remain-
ing binding) and b78 (77% of remaining binding), while
GAD65 binding by Ab CA was reduced only in the pre-
sence of rFab b78 (75% of remaining binding).
Monoclonal Ab b78 and b96.11
Metabolites in cerebellar nuclei
b78 and b96.11 increased the glutamate concentrations
in cerebellar nuclei (Figure 8A). The increase was signif-
icantly more pronounced with b78 as compared to
b96.11 (p = 0.003). The effects of both antibodies on
glucose levels in cerebellar nuclei were similar (Figure 8B).
However, glycerol levels were significantly lower with
b96.11 as compared to b78 (p = 0.021) (Figure 7C).
Cerebello-cortical inhibition
Infusion of rats (n = 2) with b78 after administration of
BFA and high-frequency stimulation of the cerebellar
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0.94%), while rats treated with b96.11 showed CCI com-
parable to control animals (0.75%) (data not shown).
Potentiation of the corticomotor response
Peripheral repetitive stimulation increased the ampli-
tudes of MEPs in animals without injection, with Ring-
er’s, and with b96.11 infusion, but not with b78 infusion
(p < 0.001, p < 0.001, p = 0.019, and p = 0.37, respec-
tively) (Figure 9). The enhancement of the corticomotor
response associated with repetitive stimulation of the
sciatic nerve was decreased with b96.11 as compared to
the enhancement in the control group (p = 0.017) and
absent with b78 as compared to the control group (p <
0.001). Amplitudes of corticomotor potentials after
Figure 2 Sigmoidal fitting of recruitment curves of motor evoked potentials (MEP). Upper panels: Ab Ctrl, middle panels: Ab CA, lower
panels: Ab SPS. Left panels: Ringer’s. Right panels: BFA. Amplitudes are expressed in mV. Dash: 95% prediction band, dotted: 95% confidence
band, p < 0.01 for each side. R
2 value > 0.970 (p < 0.005).
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higher in rats injected with b96.11 as compared to rats
injected with b78 (p = 0.024).
Effects of tDCS
tDCS induced a diffuse and marked increase of the
intensity of corticomotor responses following admin-
istration of b78, as compared to administration
of Ringer’s. The increase was milder with b96.11
(Figure 10).
F/M Ratios
A highly significant increase of F/M ratios with b78 or
b96.11 as compared to control rats with no injection (p
< 0.001 and 0.022, respectively) (Figure 11) and rats
with Ringer’s administration (p < 0.001 and 0.015,
Figure 3 Cerebello-cortical inhibition. Thin trace: no conditioning stimulus; thick trace: test stimulus with conditioning stimulus. Left panels:
baseline, middle panels: high-frequency, right panels: trains of tDCS. Microinjection of Ab Ctrl in A and B; Ab CA in C and D; Ab SPS in E and F.
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tion with b78 were significantly higher than those for
b96.11 (p = 0.011).
The effects of the different polyclonal and monoclonal
antibodies on the various parameters are summarized in
Table 2.
Discussion
The main finding of this study is that GAD65-Ab
induced degree of impairment of neurological functions
in vivo depends on the epitope specificity of the respec-
tive GAD65-Ab. To study the effect of disease- and epi-
tope-specific GAD65-Ab on neurological functions in
vivo, we utilized purified IgG from the serum of a CA
Figure 4 Cerebello-cortical inhibition (CCI). Condition 1: baseline,
Condition 2: high-frequency stimulation of the cerebellar cortex,
Condition 3: trains of tDCS. BFA and high-frequency stimulation of
the cerebellar cortex in rats injected with Ab CA (triangles), Ab Ctrl
(circles), and Ab SPS (squares). Values are mean +/- SD. *: p < 0.05.
Figure 5 Motor maps (contour plots and color code). X-axis: sagittal coordinates, Y-axis coronal coordinates, Z-axis: corticomotor responses
recorded in the contralateral gastrocnemius muscle. So-called “hot spots” (red) are identified. Coordinates of stimulation are established using
the stereotactic frame. Maximal responses set at 100% on each side. Left panels: basal, right panels: high-frequency and trains of tDCS.
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antibodies, of which only one (b78) inhibited the
enzyme activity of GAD65. GAD65Ab present in Ab
SPS and Ab CA showed different GAD65Ab binding
pattern, while also demonstrating some overlap in
GAD65Ab epitopes. This finding is in agreement that
GAD65Ab in patients are oligo- or polyclonal and thus
recognize a wide range of epitopes. The differences in
epitope specificities between the two sera was clearly
demonstrated by the strong inhibitory effect of Ab SPS
on GAD65 enzyme activity, a characteristic often
observed for SPS patients [5,6,25], while Ab CA had no
effect on the enzyme activity.
In cell and tissue culture systems, IgG from patients
with neurological syndromes and GAD65-Ab suppress
GABA release, [40,41] indicating that they may change
the balance between glutamate and GABA and cause
glutamate excitotoxicity. To test this hypothesis in vivo,
we studied the effect of GAD65-Ab on the glutamate-
pathway by microdialysis. As expected, infusion of
NMDA in the cerebellar nuclei reduced the extracellular
glutamate concentration in control animals, while gluta-
mate levels were significantly higher in rats injected
with b78 and Ab SPS. The GAD65 enzyme-inhibiting
monoclonal antibody b78 also impaired glycerol turn-
over, induced changes of corticomotor excitability, and
impaired spinal cord function. These results suggest that
inhibition of GAD65 enzyme activity could be responsi-
ble for neurochemical and neurophysiological deficits as
already suggested [12]. Inhibition of GAD65 enzyme
activity could induce the accumulation of the substrate
glutamate, leading to glutamate excitotoxicity. However,
another potential mechanism for b78 could be through
the interference with GAD65-mediated exocytosis of
GABA-containing vesicles. Indeed, many arguments sug-
gest that GAD65 may play a specific role in the control
of the synaptic release of GABA. GAD65 is localized to
the nerve termini and is reversibly bound to the mem-
brane of synaptic vesicles [42-44]. Interestingly, studies
in GAD65 knock out mice showed that both the quantal
size and frequency of GABA-mediated miniature
Figure 6 Mean F/M ratios. Group 1: Ab Ctrl+Ringer’s, left side;
Group 2: Ab Ctrl+BFA, right side; Group 3: Ab CA+Ringer’s, left side;
Group 4: Ab CA+BFA, right side; Group 5: Ab SPS+Ringer’s, left side;
Group 6: Ab SPS+BFA, right side. White bars: baseline, dash: high-
frequency stimulation, black: tDCS. Means (+/- SD) are illustrated.
Ratios are in %. *: p < 0.05, **: p < 0.01.
Figure 7 GAD65 enzyme inhibition and epitope specificity of
Ab SPS, Ab CA, and Ab Ctrl. A: Enzyme activity in the presence of
Ab SPS, Ab CA, and Ab Ctrl is reported as percent activity with
enzyme activity in the absence of Ab set as 100%. B: Binding of Ab
SPS and Ab CA to radiolabeled GAD65 in the presence of rFab b78
and b96.11 is reported as percent binding with uncompeted
binding set at 100%.
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normal in these knock out mice, but that GABA is
reduced during sustained stimulation [42,43,45], an
observation in accordance with the effects of our antibo-
dies. Thus binding of GAD65 by antibodies may inter-
fere with the transport and docking of the GABA-
containing vesicles. Our observation of a reduced mem-
brane turnover by b78 and Ab CA supports this hypoth-
esis. While the exact function of GAD65 in the synaptic
release of GABA remains unclear, our data strongly
indicate that GAD65 plays a major role in this process.
Interestingly, a recent study demonstrated that antibodies
to amphiphysin, which are associated with paraneoplastic
SPS, can access neurons and inhibit neurotransmitter
release, in vitro and in vivo, with a mechanism very similar
with our antibodies effects [17]. While our results are in
agreement with the hypothesis of a GAD65Ab-mediated
pathogenesis, we cannot exclude that the patients’ sera
also contain antibodies directed to GABA(A)-receptor-
associated protein, as have been reported in SPS patients
[46]. However, the correspondence between effects pro-
duced by the sera and the purified monoclonal antibodies
support our notion of a pathogenic role of GAD65Ab.
Another interesting point of our results was that intra-
cerebellar injection of b78 abolished the adaptation of
the motor cortex. The cerebellum plays a key role in the
increase of the cortical motor response normally
induced by repeated somatosensory stimulation in
rodents [14]. The modulation of this response is
Figure 8 Concentrations of glutamate, glucose, and glycerol in
cerebellar nuclei. A: Concentrations of glutamate in control rats,
rats receiving b96.11, and b78. Values are mean +/- SD. **: p < 0.01.
B: glucose concentrations in cerebellar nuclei during NMDA
challenge following infusion of b96.11 and b78. C: glycerol
concentrations following administration of b96.11 and b78. Values
are mean +/- SEM for glucose, median +/- SEM for glycerol.
*: p < 0.05.
Figure 9 Modulation of the excitability of the motor cortex.
Control: no cerebellar intervention; Ringer: intra-cerebellar
administration of Ringer’s; b78: administration of b78; b96.11
administration of b96.11. Recordings in gastrocnemius muscle,
before (black columns) and after ipsilateral intra-cerebellar
microinjections (white columns). *: p < 0.05; **: p < 0.01.
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of sustained peripheral stimulation [13,15,39]. The effect
of b78 intracerebellar injection shows that the adapta-
tion of the cortical motor response following a repetitive
somatosensory stimulation is dependent on the GABAe-
ric Purkinje-cerebellar nuclei synapses. The increase in
F/M ratios was significantly greater with b78, which
inhibits GAD65 enzyme activity, as compared to b96.11,
which has no effect on GAD65 enzyme activity, further
suggesting the dependence of this process on GAD65
function and GABA production and/or release. We
showed previously that IgG from GAD65-Ab positive
individuals without CNS involvement were ineffective in
changing the F/M ratios [12]. Our results provide an
explanation for the distinct phenotypes presented by
GAD65-Ab from SPS patients and CA patients. Indeed,
we observed that glutamate levels were higher in rats
treated with Ab SPS, whereas the turnover of mem-
branes was impaired by Ab CA. We hypothesize that
the latter is caused by an inhibition of membrane
Figure 10 Effects of tDCS on the amplitudes of motor evoked potentials (contour plots). X-axis: sagittal coordinates, Y-axis coronal
coordinates, Z-axis: intensities of corticomotor responses. Coordinates of stimulation are established using the stereotactic frame. Responses are
expressed as % of baseline. Upper left: control rat; upper right: Ringer’s; lower left: b78; lower right: b96.11.
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through the use of BFA and a high-frequency stimula-
tion procedure. Our data show that some GAD65-Ab
induce a vulnerability to high-frequency stimulation in
terms of dependence of endosomal recycling. Experi-
ments with BFA confirmed a BFA-dependence in the
presence of Ab CA, indicating that these antibodies
induced a state of dependence to compensatory
mechanisms of exocytosis. This could also explain why
symptoms of SPS may improve with immunotherapy
and IgG-depleting strategies, while symptoms of cerebel-
lar dysfunction rarely improve [20-22]. Indeed, the cas-
cade of events induced by antibodies differs in both
conditions.
Finally, our results suggest new strategies to study
neuronal loops controlling corticomoto-neuronal excit-
ability. Continuous or intermittent anodal tDCS induces
a polarity-dependent modulation of brain activity. The
functional modifications observed with anodal tDCS are
site-specific. Anodal stimulation increases cortical excit-
ability, by reducing intra-cortical inhibition and by aug-
menting facilitation [47]. The activity of the motor
cortex is greatly dependent on the balance between exci-
tatory and inhibitory influences over the network of cor-
tical connections. The cerebellothalamocortical pathway
is the most probable candidate for providing the input
for gating the information flow. Cerebellar information
is guided to the primary motor cortex via the ventro-lat-
eral thalamic group, which projects mainly to layers IV
and V [48]. Through this channel, inputs can adjust the
features of the circuitry of the motor cortex in various
contexts. We show that monoclonal GAD65-Ab
impaired the excitability of the motor cortex and that
tDCS enhances this perturbation, particularly with b78.
This is a new method to explore the consequences of
GAD65-Ab upon corticomotoneuronal excitability.
Conclusions
Our previous results strongly supported the hypothesis
that antibodies are directly involved in the pathogenesis
of SPS and CA [12]. We now show that GAD65-Ab
could be directly responsible for this defect and that the
epitope specificity of the GAD65-Ab is crucial to explain
the development of different neurological syndromes.
Further work will be necessary to understand how IgG
can be internalized by neurons and how the GAD65-Ab
can modify production and synaptic release of GABA.
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